{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:11:24Z","timestamp":1793373084012,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jaci.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T21:46:50Z","timestamp":1662068810000},"page":"766-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Biologics for allergic and immunologic diseases"],"prefix":"10.1016","volume":"150","author":[{"given":"Hideaki","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.08.009_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib2","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","article-title":"Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab","volume":"141","author":"Gill","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2020.04.024","article-title":"Environmental factors in epithelial barrier dysfunction","volume":"145","author":"Celebi S\u00f6zener","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib5","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1016\/j.jaip.2021.07.045","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy","volume":"9","author":"Corren","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib6","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib8","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib10","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib11","first-page":"CD12920","article-title":"Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma","volume":"10","author":"Gallagher","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2022.08.009_bib12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib13","first-page":"725","article-title":"Biologics for chronic rhinosinusitis","volume":"3","author":"Chong","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2022.08.009_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2020.05.037","article-title":"T H cell diversity and response to dupilumab in patients with atopic dermatitis","volume":"147","author":"Trichot","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jaci.2020.11.022","article-title":"Elevated NK-cell transcriptional signature and dysbalance of resting and activated NK cells in atopic dermatitis","volume":"147","author":"M\u00f6bus","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaip.2021.10.050","article-title":"COVID-19 symptoms are attenuated in moderate-to-severe atopic dermatitis patients treated with dupilumab","volume":"10","author":"Ungar","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib17","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib18","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.anai.2020.12.004","article-title":"Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: a phase 2b randomized study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cgh.2020.03.036","article-title":"Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis","volume":"19","author":"Dellon","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2022.08.009_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jaci.2020.03.045","article-title":"An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: phase 2 trial results","volume":"146","author":"Gann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib21","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1016\/j.jaip.2021.06.049","article-title":"Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome","volume":"9","author":"Dixit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib22","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2021.05.043","article-title":"Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib23","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2021.02.009","article-title":"Benralizumab for adolescent patients with severe, eosinophilic asthma: safety and efficacy after 3 years of treatment","volume":"148","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib26","first-page":"2913","article-title":"Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib27","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.jaip.2021.07.049","article-title":"Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP","volume":"9","author":"Briegel","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib33","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2020.09.024","article-title":"Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis","volume":"147","author":"Lipworth","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.08.009_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jaci.2020.09.025","volume":"147","author":"Gevaert","year":"2021","journal-title":"Reply. J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib38","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib39","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.jaci.2021.02.039","article-title":"Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab","volume":"147","author":"MacGlashan","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib40","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.jaci.2021.02.038","article-title":"The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes","volume":"147","author":"Johal","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jaci.2020.11.005","article-title":"A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis","volume":"147","author":"Carter","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib43","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in severe asthma - a phase 2a, placebo-controlled trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib44","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jaci.2021.02.041","article-title":"Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients","volume":"148","author":"Rodriguez-Rosales","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib46","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaci.2021.07.024","article-title":"Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaci.2020.09.021","article-title":"Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis","volume":"147","author":"Krueger","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib48","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib49","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2021.05.039","article-title":"Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2021.05.038","article-title":"Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response","volume":"149","author":"Atanasio","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib53","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1164\/rccm.202011-4107OC","article-title":"Passive prophylactic administration with a single dose of anti-Fel d 1 monoclonal antibodies REGN1908-1909 in cat allergen-induced allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial","volume":"204","author":"Shamji","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib55","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2022.08.009_bib58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib59","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib61","first-page":"35","article-title":"Efficacy and safety of fevipiprant in patients with uncontrolled asthma: two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)","author":"Castro","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaci.2022.08.009_bib62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2021.07.008","article-title":"Emerging targeted therapeutics underscore immunologic heterogeneity of asthma","volume":"148","author":"Tamari","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaci.2021.11.021","article-title":"Considering biomarkers in asthma disease severity","volume":"149","author":"Custovic","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib64","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Fr\u00f8ssing","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.08.009_bib65","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jaci.2021.10.003","article-title":"Relationship between type 2 cytokine and inflammasome responses in obesity-associated asthma","volume":"149","author":"Pinkerton","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib66","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.08.009_bib67","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2020.12.652","article-title":"Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation","volume":"148","author":"Delgado-Eckert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib68","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","article-title":"PrecISE: Precision medicine in severe asthma: an adaptive platform trial with biomarker ascertainment","volume":"147","author":"Israel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib69","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jaci.2021.01.021","article-title":"Endotyping chronic rhinosinusitis based on olfactory cleft mucus biomarkers","volume":"147","author":"Soler","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib70","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaci.2021.01.001","article-title":"The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults","volume":"148","author":"Renert-Yuval","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","article-title":"Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers","volume":"147","author":"Bakker","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2021.04.010","article-title":"Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma","volume":"149","author":"Badi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib74","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.jaci.2020.10.037","article-title":"Combination blockade of OX40L and CD30L inhibits allergen-driven memory TH2 cell reactivity and lung inflammation","volume":"147","author":"Gracias","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib75","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib77","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jaci.2021.09.005","article-title":"Racial\/ethnic differences in eligibility for asthma biologics among pediatric populations","volume":"148","author":"Wohlford","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib78","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jaci.2021.09.006","article-title":"Addressing disparities in biologic drug development in the United States","volume":"148","author":"Hvisdas","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.08.009_bib79","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2020.11.012","article-title":"De Las Vecillas L, Castells M, Santander B, Boston S; Non-IgE adverse reactions to biologics","volume":"147","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922011174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674922011174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:37:48Z","timestamp":1758793068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674922011174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0091674922011174"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.08.009","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for allergic and immunologic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}